


Prior Authorization (PA) Considerations

Some health plans may require a PA evaluation and approval before providing coverage

This resource is provided to support patient access to ORGOVYX. It is for informational purposes only and is not intended to provide recommendations. This is not a comprehensive description of potential payer access and coding requirements for ORGOVYX. The prescriber is solely responsible for coding, determining coverage/reimbursement requirements, and submitting the necessary information to payers. Sumitomo Pharma America and Pfizer do not make any representation or guarantee concerning reimbursement, coverage, or coding for any item or service. Nothing within this resource is intended to be a substitute for, or influence on, prescribers' independent medical judgment.



*This coverage information is provided for informational purposes only; individual plans vary, and this may not include all plans. Sumitomo Pharma America and Pfizer make no representation or guarantee concerning coverage or reimbursement; please check with individual payers for plan-specific coverage and reimbursement information and requirements. Nothing herein may be construed as an endorsement, approval, recommendation, representation, or warranty of any kind by any plan or insurer referenced. This information is subject to change without notice.

Understanding PA requirements after you prescribe ORGOVYX

When you prescribe ORGOVYX for the treatment of advanced prostate cancer, fill the prescription the way you normally do. Your patient's health plan may require a PA before coverage is approved for ORGOVYX. In such cases, the patient's health plan has certain requirements that must be met to determine whether the medication is covered for the particular patient. Inside this resource, healthcare providers can find information regarding:



Considerations for submitting a PA



ICD-10-CM code information



Examples of PA criteria for ORGOVYX

ICD-10-CM=International Classification of Diseases, Tenth Revision, Clinical Modification.

INDICATION

ORGOVYX[®] (relugolix) is a gonadotropin-releasing hormone (GnRH) receptor antagonist indicated for the treatment of adult patients with advanced prostate cancer.

IMPORTANT SAFETY INFORMATION

Contraindication

ORGOVYX is contraindicated in patients with severe hypersensitivity to relugolix or to any of the product components.

Please see Important Safety Information throughout and full Prescribing Information for ORGOVYX.

Prescriber considerations for submitting a PA



Reminders and tips when completing a PA for your patients

Each health plan may have its own unique PA form with varying requirements. It is important to gather necessary information during the patient's first appointment to ensure successful navigation of the process with minimal delays.

This necessary information may include, but is not limited to:

- Patient demographics (date of birth, gender, phone, email, and address)
- Patient insurance information (copy front and back of patient's prescription [drug] and health [medical] card)
- Patient health charts and past medical history
 - Including comorbidities and treatment history (PSA, lab results, imaging, treatment plan)

Remember: Submit a PA through a patient's pharmacy benefit.



Drug information

Prescribed by:

Radiation oncologist
Medical oncologist
Urologist

Prescription information:

Quantity
Days supplied

Diagnosis coding*



Remember, most payers require inclusion of an ICD-10-CM diagnosis code in order to evaluate PA submissions and determine coverage



Scan or click the QR code to search for ICD-10-CM codes.

FDA=US Food and Drug Administration; ICD-10-CM=International Classification of Diseases, Tenth Revision, Clinical Modification; PA=prior authorization; PSA=prostate-specific antigen.

*The ICD-10-CM information provided above is intended for informational purposes only and is not a comprehensive list of potential coding requirements for ORGOVYX. Coding and coverage policies change periodically and often without warning. The healthcare provider is solely responsible for determining coverage and reimbursement parameters and accurate and appropriate coding for treatment of his/her patients. The information provided in this section should not be considered a guarantee of coverage or reimbursement for ORGOVYX. The code shown above is only a general suggestion and is not intended to encourage or suggest a use of any drug that is inconsistent with FDA-approved use.

IMPORTANT SAFETY INFORMATION (cont'd)


Warnings and Precautions

QT/QTc Interval Prolongation: Androgen deprivation therapy, such as ORGOVYX may prolong the QT/QTc interval. Providers should consider whether the benefits of androgen deprivation therapy outweigh the potential risks in patients with congenital long QT syndrome, congestive heart failure, or frequent electrolyte abnormalities and in patients taking drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected. Consider periodic monitoring of electrocardiograms and electrolytes.

Hypersensitivity: Angioedema was reported in 0.2% of patients treated with ORGOVYX in HERO. Hypersensitivity reactions, including pharyngeal edema and other serious cases of angioedema, have been reported post-marketing with ORGOVYX. Advise patients who experience any symptoms of hypersensitivity to temporarily discontinue ORGOVYX and promptly seek medical care. Discontinue ORGOVYX for severe hypersensitivity reactions and manage as clinically indicated.

Please see Important Safety Information throughout and full Prescribing Information for ORGOVYX.

Examples of PA criteria questions



For most insurance plans nationally (ie, commercial and Medicare Part D), **ORGOVYX is covered with no step therapy**¹

These examples are provided for informational purposes only and are not a complete list of criteria that a health plan may consider when making coverage decisions. It is the prescriber's responsibility to verify payer-specific PA criteria to ensure accuracy/completeness, as requirements may change over time.



Common patient history questions

- Is the patient 18 years of age or older?
- Is the patient diagnosed with advanced prostate cancer?



Less common patient history questions

- Is the patient at risk for cardiovascular disease?
- Is the patient not a candidate for another ADT?
- Is the patient currently receiving therapy with ORGOVYX?
- Is the patient using intermittent ADT?



Reauthorization questions for continuation

Some health plans may require periodic reauthorization of a patient's therapy as part of the plan's assessment to continue treatment coverage.

- Has the patient experienced a clinical benefit from ORGOVYX therapy?
- Does the patient show evidence of progressive disease while on ORGOVYX therapy?
- Has the patient experienced an unacceptable level of toxicity to ORGOVYX therapy?

ADT=androgen deprivation therapy; PA=prior authorization.

IMPORTANT SAFETY INFORMATION (cont'd)

Warnings and Precautions (cont'd)

Embryo-Fetal Toxicity: The safety and efficacy of ORGOVYX have not been established in females. Based on findings in animals and mechanism of action, ORGOVYX can cause fetal harm and loss of pregnancy when administered to a pregnant female. Advise males with female partners of reproductive potential to use effective contraception during treatment and for 2 weeks after the last dose of ORGOVYX.

Laboratory Testing: Therapy with ORGOVYX results in suppression of the pituitary gonadal system. Results of diagnostic tests of the pituitary gonadotropic and gonadal functions conducted during and after ORGOVYX may be affected. The therapeutic effect of ORGOVYX should be monitored by measuring serum concentrations of prostate-specific antigen (PSA) periodically. If PSA increases, serum concentrations of testosterone should be measured.

Please see Important Safety Information throughout and full Prescribing Information for ORGOVYX.

ORGOVYX[®]
(relugolix) 120 mg tablets

The ORGOVYX Support Program is dedicated to providing ongoing support to help patients prescribed ORGOVYX

ORGOVYX SUPPORT PROGRAM



For questions or 1:1 support, contact your Reimbursement Manager (RM), who can:

- Actively monitor the PA process and will reach out to HCPs to offer support
- Set up meetings with office staff to help them learn more about ORGOVYX Support Program offerings
- Provide office staff with information about the patient's specific health plan and requirements
- Keep office staff informed of any missing information for the coverage approval
- Help address coverage questions or situations



Learn more by calling 1-833-ORGOVYX (1-833-674-6899), Monday–Friday, 8 AM–8 PM ET.

IMPORTANT SAFETY INFORMATION (cont'd)

Adverse Reactions

Serious adverse reactions occurred in 12% of patients receiving ORGOVYX. Serious adverse reactions in $\geq 0.5\%$ of patients included myocardial infarction (0.8%), acute kidney injury (0.6%), arrhythmia (0.6%), hemorrhage (0.6%), and urinary tract infection (0.5%). Fatal adverse reactions occurred in 0.8% of patients receiving ORGOVYX including metastatic lung cancer (0.3%), myocardial infarction (0.3%), and acute kidney injury (0.2%). Fatal and non-fatal myocardial infarction and stroke were reported in 2.7% of patients receiving ORGOVYX.

Most common adverse reactions ($\geq 10\%$) and laboratory abnormalities ($\geq 15\%$) in patients receiving ORGOVYX were hot flush (54%), glucose increased (44%), triglycerides increased (35%), musculoskeletal pain (30%), hemoglobin decreased (28%), alanine aminotransferase increased (27%), fatigue (26%), aspartate aminotransferase increased (18%), constipation (12%), and diarrhea (12%).

Drug Interactions

Co-administration of ORGOVYX with an oral P-gp inhibitor increases relugolix exposure, which may increase the risk of adverse reactions associated with ORGOVYX. Avoid co-administration of ORGOVYX with oral P-gp inhibitors. If co-administration is unavoidable, take ORGOVYX first and separate dosing by at least 6 hours. Monitor patients for increased adverse reactions. Treatment with ORGOVYX may be interrupted for up to 2 weeks if a short course of treatment with a P-gp inhibitor is required. Resume ORGOVYX after the P-gp inhibitor is discontinued. If treatment with ORGOVYX is interrupted for greater than 7 days, restart ORGOVYX with a 360 mg loading dose on the first day and continue with 120 mg once daily.

Co-administration of ORGOVYX with a combined P-gp and strong CYP3A inducer decreases relugolix exposure, which may reduce the effects of ORGOVYX. Avoid co-administration of ORGOVYX with combined P-gp and strong CYP3A inducers. If co-administration is unavoidable, increase the ORGOVYX dose to 240 mg once daily. After discontinuation of the combined P-gp and strong CYP3A inducer, resume the recommended ORGOVYX dose of 120 mg once daily.

Please see full [Prescribing Information](#) for ORGOVYX.

HCP=healthcare provider; PA=prior authorization.

Reference: 1. Data on file. Formulary data provided by MMIT, LLC, as of August 2025. Sumitomo Pharma America, Inc.



◆ is a trademark of Sumitomo Pharma Co., Ltd., used under license.
SUMITOMO PHARMA is a trademark of Sumitomo Pharma Co., Ltd., used under license.
SUMITOMO is a registered trademark of Sumitomo Chemical Co., Ltd., used under license.
Sumitomo Pharma America, Inc. is a U.S. subsidiary of Sumitomo Pharma Co. Ltd.
ORGOVYX® and its logo are registered trademarks of Sumitomo Pharma Co. Ltd., used under license.
All other trademarks are the property of their respective owners.
© 2025 Sumitomo Pharma America, Inc. and Pfizer Inc.
All rights reserved. ORG-US-0306-25 11/25

ORGOVYX
(relugolix) 120 mg
tablets